Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24806043 | 0.98 | PDE4A (0.53) | CA12CA1CA2CA4CA7 | |
| SCHEMBL29340231 | 0.96 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL16946799 | 0.91 | CA1 (0.59) | CA12CA1CA2CA4CA7 | |
| Ammonia Solution, Strong SCHEMBL7413397 | 0.89 | CA12 (0.56) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5344402 | 0.89 | MCHR1 (0.49) | PDE4APDE4BPDE4CPDE4D | |
| Methylamine SCHEMBL7433365 | 0.88 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2242864 | 0.87 | MCHR1 (0.51) | PDE4APDE4BPDE4CPDE4D | |
| Formic Acid SCHEMBL28316720 | 0.86 | PDE4B (0.48) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL1780546 | 0.82 | HRH1 (0.62) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2093016 | 0.82 | CA12 (0.48) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3806441-B2 | — | — | 2006-08-09 | — | — | JP | claimed |
| EP-0618889-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1994-10-12 | — | — | EP | claimed |
| WO-1994010118-A1 | TRI-SUBSTITUTED PHENYL DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH LIMITED (GB) | 1994-05-11 | — | — | WO | claimed |
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115197191-A | Novel traditional Chinese medicine flavone derivative and preparation method and application thereof | 中国海洋大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-106390128-B | Use of beta-adrenergic inverse agonists for smoking cessation | 伊沃恩有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | GOETHE-UNIVERSITY FRANKFURT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-18 | — | — | US | disclosed |
| WO-2019147824-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PROGENITY, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019079609-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | WO | disclosed |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| EP-1244619-A1 | PYRROLIDINES WHICH INHIBIT CAMP-SPECIFIC PDE | ICOS CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047879-A1 | PYRROLIDINES WHICH INHIBIT CAMP-SPECIFIC PDE | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-0799187-A4 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-CARBOXYLATE DIMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-03-25 | — | — | EP | disclosed |
| EP-0799187-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-CARBOXYLATE DIMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| EP-0787132-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES AND THEIR USE AS MEDICAMENTS | PFIZER INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996020163-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-CARBOXYLATE DIMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996012720-A1 | BICYCLIC TETRAHYDRO PYRAZOLOPYRIDINES AND THEIR USE AS MEDICAMENTS | PFIZER INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | EPHX1, PDE4A, EPHX2 | CA12 2764/4885CA1 2245/4885CA2 1898/4885 |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | CA12 4751/4885CA1 2694/4885CA2 3702/4885 |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | CA12 4751/4885CA1 2694/4885CA2 3702/4885 |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | EPHX1, PDE4A, EPHX2 | CA12 2764/4885CA1 2245/4885CA2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.